A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Finding the right balance between safety and returns isn’t easy, which is why StockStory is here to help. Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two that may not deliver the returns you need.
Two Stocks to Sell:
NeoGenomics (NEO)
Rolling One-Year Beta: 0.89
Operating a network of CAP-accredited and CLIA-certified laboratories across the United States and United Kingdom, NeoGenomics (NASDAQ: NEO) provides specialized cancer diagnostic testing services, including genetic analysis, molecular testing, and pathology consultation for oncologists and healthcare providers.
Why Should You Sell NEO?
- Smaller revenue base of $689.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Push for growth has led to negative returns on capital, signaling value destruction, and its shrinking returns suggest its past profit sources are losing steam
- Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders
NeoGenomics’s stock price of $8.32 implies a valuation ratio of 34.8x forward P/E. To fully understand why you should be careful with NEO, check out our full research report (it’s free).
Globe Life (GL)
Rolling One-Year Beta: 0.52
With roots dating back to 1900 and a rebranding from Torchmark Corporation in 2019, Globe Life (NYSE: GL) is an insurance holding company that offers life insurance, supplemental health insurance, and annuity products through various distribution channels.
Why Are We Hesitant About GL?
- Annual revenue growth of 4.6% over the last two years was below our standards for the insurance sector
- 4.4% annualized net premiums earned growth over the last two years lagged behind its insurance peers
- Policy losses and capital returns have eroded its book value per share this cycle as its book value per share declined by 2.4% annually over the last five years
At $142.49 per share, Globe Life trades at 2x forward P/B. If you’re considering GL for your portfolio, see our FREE research report to learn more.
One Stock to Buy:
Inter Parfums (IPAR)
Rolling One-Year Beta: 0.91
With licenses to produce colognes and perfumes under brands such as Kate Spade, Van Cleef & Arpels, and Abercrombie & Fitch, Inter Parfums (NASDAQ: IPAR) manufactures and distributes fragrances worldwide.
Why Is IPAR a Top Pick?
- Annual revenue growth of 14.6% over the last three years beat the sector average and underscores the popularity of its brand
- Free cash flow margin expanded by 8.7 percentage points over the last year, providing additional flexibility for investments and share buybacks/dividends
- Industry-leading 27.4% return on capital demonstrates management’s skill in finding high-return investments
Inter Parfums is trading at $108.53 per share, or 20.1x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it’s free.
Stocks We Like Even More
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
